{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:32:46Z","timestamp":1794623566127,"version":"4.9.1"},"reference-count":196,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.autrev.2023.103332","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T19:51:12Z","timestamp":1681501872000},"page":"103332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders"],"prefix":"10.1016","volume":"22","author":[{"given":"Ludovico","family":"De Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Bobbio","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mauric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Vismara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/RHU.0000000000000617","article-title":"Low doses of Etanercept can be effective to maintain remission in psoriatic arthritis patients","volume":"24","author":"de Stefano","year":"2018","journal-title":"J. Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0040","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1093\/rheumatology\/keab771","article-title":"Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib","volume":"61","author":"De Stefano","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0045","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with Dupilumab is linked to some emergent T helper 17\u2013type diseases, including seronegative arthritis and Enthesitis\/Enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00296-004-0542-1","article-title":"Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity","volume":"26","author":"Caramaschi","year":"2006","journal-title":"Rheumatol. Int."},{"issue":"12","key":"10.1016\/j.autrev.2023.103332_bb0055","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0060","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar2912","article-title":"Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment","volume":"12","author":"van Baarsen","year":"2010","journal-title":"Arthrit. Res. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","article-title":"Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies","volume":"255","author":"D\u2019Auria","year":"2004","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cei.12626","article-title":"Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis","volume":"181","author":"Hull","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0075","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10875-015-0182-0","article-title":"Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response","volume":"35","author":"Talotta","year":"2015","journal-title":"J. Clin. Immunol."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162896","article-title":"Immunogenicity and lupus-like autoantibody production can be linked to each other along with type I interferon production in patients with rheumatoid arthritis treated with infliximab: a retrospective study of a single center cohort","volume":"11","author":"Ishikawa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2023.103332_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions","volume":"11","author":"Sfikakis","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0090","first-page":"88","article-title":"Paradoxical reactions to biologicals in chronic inflammatory systemic diseases","volume":"119","author":"Kremenevski","year":"2022","journal-title":"Dtsch. Arztebl. Int."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0095","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0100","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573397115666190506152729","article-title":"Antinuclear antibodies and lupus-like manifestations in rheumatoid arthritis and ankylosing spondylitis patients at 4 Months\u2019 follow-up after treatment with infliximab and Etanercept","volume":"16","author":"Aghdashi","year":"2020","journal-title":"Curr. Rheumatol. Rev."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0115","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","article-title":"Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn\u2019s disease","volume":"11","author":"Nancey","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0120","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","article-title":"Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study","volume":"6","author":"Ferraro-Peyret","year":"2004","journal-title":"Arthrit. Res. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0125","first-page":"401","article-title":"Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers","volume":"26","author":"Gonnet-Gracia","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0130","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1186\/ar1173","article-title":"Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment","volume":"6","author":"Bobbio-Pallavicini","year":"2004","journal-title":"Arthrit. Res. Ther."},{"issue":"20","key":"10.1016\/j.autrev.2023.103332_bb0135","first-page":"1227","article-title":"Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report","author":"Kolarz","year":"2014","journal-title":"Med. Sci. Monit."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0140","first-page":"2041","article-title":"Leukocytoclastic vasculitis due to etanercept","volume":"27","author":"Galaria","year":"2000","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0145","first-page":"1955","article-title":"Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents","volume":"31","author":"Mohan","year":"2004","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","article-title":"Vasculitis associated with tumor necrosis factor-\u03b1 inhibitors","volume":"87","author":"Sokumbi","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2169\/internalmedicine.5340-20","article-title":"Intermittent Purpura Development Associated with Leukocytoclastic Vasculitis Induced by Infliximab for Crohn\u2019s Disease","volume":"60","author":"Kishimoto","year":"2021","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0165","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","article-title":"IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-\u03b1 blockers","volume":"61","author":"Rasmussen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102707","article-title":"Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach","volume":"20","author":"Rasmussen","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2023.103332_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.617312","article-title":"Case report: systemic small-vessel Vasculitis in an adolescent with active ulcerative colitis","volume":"9","author":"Bouhuys","year":"2021","journal-title":"Front. Pediatr."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0180","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ecco-jcc\/jjz164","article-title":"Severe attack of Henoch-Sch\u00f6nlein Purpura with neurological involvement during adalimumab treatment for Crohn\u2019s disease","volume":"14","author":"Condamina","year":"2020","journal-title":"J. Crohns Colit."},{"issue":"13","key":"10.1016\/j.autrev.2023.103332_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18136711","article-title":"Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report","volume":"18","author":"Giorgio","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0190","doi-asserted-by":"crossref","first-page":"300","DOI":"10.46497\/ArchRheumatol.2022.9049","article-title":"Vasculitis induced by biological agents used in rheumatology practice: A systematic review","volume":"37","author":"da Silva Cendon Duran","year":"2022","journal-title":"Arch. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10067-022-06406-6","article-title":"Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature","volume":"42","author":"Ak","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0200","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthrit. Res. Ther."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0205","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archderm.142.1.115","article-title":"Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis","volume":"142","author":"Schneider","year":"2006","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0215","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0961203308093922","article-title":"Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?","volume":"18","author":"Kocharla","year":"2009","journal-title":"Lupus."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0225","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0230","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","article-title":"TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists","volume":"50","author":"Williams","year":"2011","journal-title":"Int. J. Dermatol."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0240","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00296-011-2137-y","article-title":"Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab","volume":"32","author":"Diaz","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0245","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.crohns.2012.06.016","article-title":"Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus in a patient with metastatic Crohn\u2019s disease--what is the role of anti-TNF antibody?","volume":"7","author":"Farkas","year":"2013","journal-title":"J. Crohns Colit."},{"issue":"12","key":"10.1016\/j.autrev.2023.103332_bb0250","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s10067-013-2361-9","article-title":"A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-\u03b1 agent?","volume":"32","author":"Santiago","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0961203313517153","article-title":"Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis","volume":"23","author":"Brunasso","year":"2014","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2023.103332_bb0260","first-page":"2015","article-title":"Adalimumab-induced lupus serositis","author":"Kelly","year":"2015","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","article-title":"Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature","volume":"37","author":"Shovman","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2023.103332_bb0270","first-page":"4324592","article-title":"Pericardial effusion due to infliximab therapy for ulcerative colitis","volume":"2018","author":"Mirza","year":"2018","journal-title":"Case Rep. Gastrointest. Med."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-019-2028-2","article-title":"Anti-TNF-alpha-induced lupus","volume":"21","author":"De Bandt","year":"2019","journal-title":"Arthrit. Res. Ther."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0280","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","article-title":"Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"20","key":"10.1016\/j.autrev.2023.103332_bb0285","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2169\/internalmedicine.4646-20","article-title":"Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-TNF-\u03b1 and IL-6 therapy in a patient with rheumatoid arthritis","volume":"59","author":"Yoshikawa","year":"2020","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0290","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jgh3.12291","article-title":"Anti-TNF-induced lupus in patients with inflammatory bowel disease","volume":"4","author":"Picardo","year":"2020","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0295","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40268-020-00320-5","article-title":"Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus","volume":"20","author":"Bolton","year":"2020","journal-title":"Drugs R D"},{"key":"10.1016\/j.autrev.2023.103332_bb0300","article-title":"Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis","volume":"10","author":"Miguel-Escuder","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0305","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00393-021-00983-8","article-title":"Anti-TNF-\u03b1-induced lupus syndrome\u202f: two case reports and review of current literature","volume":"80","author":"Sieiro Santos","year":"2021","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.autrev.2023.103332_bb0310","first-page":"9989729","article-title":"Antitumor necrosis factor-alpha (TNF-\u03b1) infliximab-induced pleural effusion and pericarditis in Crohn\u2019s disease","volume":"2021","author":"Fonseca","year":"2021","journal-title":"Case Rep. Pediatr."},{"key":"10.1016\/j.autrev.2023.103332_bb0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2021.04.006","article-title":"Clinical features of tumor necrosis factor-\u03b1-inhibitor induced chilblain lupus: a case series","volume":"12","author":"Shabeeb","year":"2021","journal-title":"JAAD Case Rep."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0320","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3899\/jrheum.170133","article-title":"The prevalence of renal impairment in patients with Spondyloarthritis: results from the international ASAS-COMOSPA study","volume":"45","author":"Couderc","year":"2018","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0325","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ekir.2020.03.012","article-title":"Spondyloarthritis-associated IgA nephropathy","volume":"5","author":"Champtiaux","year":"2020","journal-title":"Kidney Int. Rep."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-237713","article-title":"Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis","volume":"14","author":"Baert","year":"2021","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0335","first-page":"91","article-title":"Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis","volume":"28","author":"Men\u00e8","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0340","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14712\/18059694.2015.74","article-title":"Case 1-2012: ANCA associated glomerulonephritis in combination with IgG4-positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors","volume":"55","author":"Tosovsk\u00fd","year":"2012","journal-title":"Acta Med. (Hradec Kralove)"},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0345","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0350","article-title":"Etanercept-associated nephropathy","volume":"11","author":"Ammar","year":"2019","journal-title":"Cureus."},{"key":"10.1016\/j.autrev.2023.103332_bb0355","first-page":"61","article-title":"Glomerulonephritis in two patients with SpA treated with TNF-\u03b1 blockers and a review of the literature","volume":"15","author":"Bounia","year":"2021","journal-title":"Biologics."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0360","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2169\/internalmedicine.54.4188","article-title":"Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review","volume":"54","author":"Akiyama","year":"2015","journal-title":"Intern. Med."},{"key":"10.1016\/j.autrev.2023.103332_bb0365","first-page":"9480860","article-title":"The association of TNF-alpha inhibitors and development of IgA nephropathy in patients with rheumatoid arthritis and diabetes","volume":"2020","author":"Premu\u017ei\u0107","year":"2020","journal-title":"Case Rep. Nephrol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0370","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.crohns.2012.01.017","article-title":"Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease","volume":"6","author":"van Casteren-Messidoro","year":"2012","journal-title":"J. Crohns Colit."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0375","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.autrev.2012.03.010","article-title":"Drug induced autoimmune hepatitis and TNF-\u03b1 blocking agents: is there a real relationship?","volume":"12","author":"Efe","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"24","key":"10.1016\/j.autrev.2023.103332_bb0380","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ajd.12054","article-title":"Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis","volume":"55","author":"Dang","year":"2014","journal-title":"Australas J. Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0395","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000354593","article-title":"Hepatitis and lupus-like syndrome during infliximab therapy for psoriasis","volume":"5","author":"Riad","year":"2013","journal-title":"Case Rep. Dermatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0400","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.20293","article-title":"Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis","volume":"14","author":"Marques","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0405","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/03009740902832753","article-title":"Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis","volume":"39","author":"Vereckei","year":"2010","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.autrev.2023.103332_bb0410","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1752-1947-4-12","article-title":"Etanercept and venous thromboembolism: a case series","volume":"4","author":"Makol","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.autrev.2023.103332_bb0415","article-title":"Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome","volume":"2014","author":"Virupannavar","year":"2014","journal-title":"Case Rep. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0420","first-page":"546","article-title":"Arterial thrombosis with anti-phospholipid antibodies induced by infliximab","volume":"17","author":"Nosbaum","year":"2007","journal-title":"Eur. J. Dermatol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0425","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10067-013-2244-0","article-title":"Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature","volume":"32","author":"Hemmati","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0430","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","article-title":"Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology biologics register","volume":"70","author":"Davies","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0435","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/s41598-021-96508-z","article-title":"Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0440","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3899\/jrheum.091413","article-title":"Dermatomyositis during adalimumab therapy for rheumatoid arthritis","volume":"37","author":"Brunasso","year":"2010","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0445","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0450","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis","volume":"146","author":"Klein","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0455","first-page":"240","article-title":"Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis","volume":"48","author":"Ishiguro","year":"2010","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0460","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.rbr.2015.12.005","article-title":"Three cases of anti-TNF induced myositis and literature review","volume":"57","author":"Zengin","year":"2017","journal-title":"Rev. Bras. Reumatol. Engl. Ed."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/24725625.2019.1628427","article-title":"A case of granulomatous myositis in a patient with rheumatoid arthritis receiving anti-TNF-\u03b1 treatment","volume":"4","author":"Kawamura","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0470","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/24725625.2020.1800958","article-title":"Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis","volume":"5","author":"Yoshida","year":"2021","journal-title":"Mod. Rheumatol. Case Rep."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0475","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jbspin.2014.03.003","article-title":"Acute ocular myositis occurring under etanercept for rheumatoid arthritis","volume":"81","author":"Couderc","year":"2014","journal-title":"Joint Bone Spine."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0480","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0485","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.autrev.2023.103332_bb0490","article-title":"Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature","volume":"2013","author":"Andreadou","year":"2013","journal-title":"Case Rep. Neurol. Med."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0495","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0500","doi-asserted-by":"crossref","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis","year":"2014","journal-title":"Arthrit. Res. Ther."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0505","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0510","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.semarthrit.2018.09.006","article-title":"Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases","volume":"48","author":"Etminan","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0515","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0520","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1177\/1352458519895445","article-title":"Iatrogenic demyelinating disorders: new insights, new culprits","volume":"26","author":"Abboud","year":"2020","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0525","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology."},{"issue":"12","key":"10.1016\/j.autrev.2023.103332_bb0530","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0535","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0540","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of anti-TNF\u03b1 therapy in the British Society for Rheumatology biologics registry in rheumatoid arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0545","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.autrev.2023.103332_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102942","article-title":"Use of anti-TNF-\u03b1 therapy in Crohn\u2019s disease is associated with increased incidence of multiple sclerosis","volume":"51","author":"Avasarala","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0555","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1941874419859769","article-title":"Rheumatoid meningitis: clinical characteristics, diagnostic evaluation, and treatment","volume":"10","author":"Parsons","year":"2020","journal-title":"Neurohospitalist."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0560","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/fcp.12349","article-title":"Drug-induced aseptic meningitis: a mini-review","volume":"32","author":"Yelehe-Okouma","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"9295","key":"10.1016\/j.autrev.2023.103332_bb0565","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/S0140-6736(01)06810-6","article-title":"Infliximab-induced aseptic meningitis","volume":"358","author":"Marotte","year":"2001","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0570","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00296-021-04822-6","article-title":"Aseptic meningitis in rheumatoid arthritis after anti-TNF administration: a case-based literature review","volume":"41","author":"Y\u0131ld\u0131r\u0131m","year":"2021","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0575","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0580","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases","volume":"151","author":"Dereure","year":"2004","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0585","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0590","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat. Commun."},{"issue":"644","key":"10.1016\/j.autrev.2023.103332_bb0595","first-page":"668","article-title":"Paradoxical psoriasis induced by anti-TNF - a clinical challenge","volume":"15","author":"Nidegger","year":"2019","journal-title":"Rev. Med. Suisse."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0600","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14225","article-title":"Tumor necrosis factors-\u03b1 inhibition-induced paradoxical psoriasis: a case series and literature review","volume":"33","author":"Lian","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0605","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/MEG.0000000000001917","article-title":"Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy","volume":"33","author":"Nigam","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0610","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0615","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pde.14712","article-title":"Paradoxical psoriasis in pediatric patients: a systematic review","volume":"38","author":"Cyrenne","year":"2021","journal-title":"Pediatr. Dermatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0620","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1346-8138.13762","article-title":"Cutaneous side-effects of biologics in immune-mediated disorders: a histopathological perspective","volume":"44","author":"Succaria","year":"2017","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0625","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000342503","article-title":"Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature","volume":"225","author":"Os\u00f3rio","year":"2012","journal-title":"Dermatology."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0630","first-page":"E48","article-title":"Psoriatic alopecia in a patient with Crohn disease: an uncommon manifestation of tumor necrosis factor \u03b1 inhibitors","volume":"107","author":"Carrasquillo","year":"2021","journal-title":"Cutis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0635","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2020.01.006","article-title":"Histologic comparison of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis and psoriasis vulgaris","volume":"83","author":"Hu","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0640","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cup.14113","article-title":"Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents","volume":"49","author":"Navarro","year":"2022","journal-title":"J. Cutan. Pathol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0645","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaad.2020.06.081","article-title":"Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: a case-control study","volume":"83","author":"Ya","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0650","doi-asserted-by":"crossref","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0655","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms","volume":"56","author":"Sherlock","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0660","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1523-1747.1999.00724.x","article-title":"HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies","volume":"113","author":"Mallon","year":"1999","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.autrev.2023.103332_bb0665","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/ijd.14072","article-title":"Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review","volume":"57","author":"Melo","year":"2018","journal-title":"Int. J. Dermatol."},{"issue":"21","key":"10.1016\/j.autrev.2023.103332_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.autrev.2023.103332_bb0675","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-0716-1130-2_11","article-title":"Experimental methods for the immunological characterization of paradoxical psoriasis reactions induced by TNF-\u03b1 biologics","volume":"2248","author":"Morelli","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0680","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000506074","article-title":"Paradoxical hidradenitis Suppurativa in patients receiving TNF-\u03b1 inhibitors: case series, systematic review, and case Meta-analysis","volume":"236","author":"Salvador-Rodriguez","year":"2020","journal-title":"Dermatology."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0685","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","article-title":"Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab","volume":"38","author":"Skalkou","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0690","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13555-020-00398-4","article-title":"Paradoxical skin reaction to Certolizumab, an overlap of pyoderma Gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review","volume":"10","author":"Gawdzik","year":"2020","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0695","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1093\/rheumatology\/keab194","article-title":"Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?","volume":"60","author":"Tan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0700","first-page":"203","article-title":"Granuloma Annulare, a possible paradoxical reaction of the adalimumab treatment in a severe case of psoriasis vulgaris","volume":"46","author":"M\u0102rculescu F, P\u0102tra\u0218cu V, Tutunaru CV, Ochiana L.","year":"2020","journal-title":"Curr. Health Sci. J."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0705","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/ced.14751","article-title":"Systemic sarcoidosis reactions as a result of tumour necrosis factor-alpha treatment for patients with psoriasis","volume":"46","author":"Bewley","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.autrev.2023.103332_bb0710","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1007\/s10067-021-05654-2","article-title":"Adalimumab-induced sarcoidosis-like reaction involving oral cavity in rheumatoid arthritis: a case-based review","volume":"40","author":"Rodrigues-Fernandes","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0715","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0000000000000800","article-title":"Drug-induced sarcoidosis-like reactions","volume":"27","author":"Miedema","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"7\u20138","key":"10.1016\/j.autrev.2023.103332_bb0720","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/09273948.2021.1961813","article-title":"Late-onset Etanercept-associated ocular sarcoidosis with profound vision loss","volume":"30","author":"Saifee","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0725","first-page":"1590","article-title":"Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis","volume":"34","author":"van Ede","year":"2007","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0730","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.medcli.2016.11.002","article-title":"Rheumatoid lung nodulosis during anti-TNF therapy","volume":"148","author":"Zurita Prada","year":"2017","journal-title":"Med. Clin. (Barc.)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0735","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/03009740410005836","article-title":"Severe interstitial pneumonitis associated with infliximab therapy","volume":"33","author":"Chatterjee","year":"2004","journal-title":"Scand. J. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0740","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0745","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3899\/jrheum.131026","article-title":"Extraarticular manifestations of rheumatoid arthritis develop in patients receiving anti-tumor necrosis factor-\u03b1 treatment: a retrospective chart review from a UK center","volume":"41","author":"Negoescu","year":"2014","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0750","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3899\/jrheum.141273","article-title":"Extraarticular manifestations of rheumatoid arthritis in patients under anti-tumor necrosis factor-\u03b1 treatment","volume":"42","author":"Bachmeyer","year":"2015","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0755","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3899\/jrheum.161103","article-title":"Severe Extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors","volume":"44","author":"Theander","year":"2017","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0760","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00393-004-0537-z","article-title":"Development and\/or increase of rheumatoid nodules in RA patients following leflunomide therapy","volume":"63","author":"Braun","year":"2004","journal-title":"Z. Rheumatol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0765","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00296-009-1240-9","article-title":"Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature","volume":"31","author":"Kim","year":"2011","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0770","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/14397595.2014.928424","article-title":"Nodules in patients with rheumatoid arthritis and methotrexate treatment","volume":"25","author":"Nakamura","year":"2015","journal-title":"Mod. Rheumatol."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0775","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J. Ophthalmic. Inflamm. Infect."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0785","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0790","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0795","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0800","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/03009742.2010.499878","article-title":"Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab","volume":"40","author":"Tarkiainen","year":"2011","journal-title":"Scand. J. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0805","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0810","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/MJT.0b013e31825e6089","article-title":"Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature","volume":"21","author":"Bawany","year":"2014","journal-title":"Am. J. Ther."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0815","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by Etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0820","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gastrohep.2016.01.011","article-title":"Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy","volume":"40","author":"Iriarte","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0825","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.160952","article-title":"Antitumor necrosis factor-\u03b1 therapy associated with inflammatory bowel disease: three cases and a systematic literature review","volume":"44","author":"Bieber","year":"2017","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0830","first-page":"262","article-title":"Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? Real life data","volume":"111","author":"\u00dcsk\u00fcdar Cansu","year":"2019","journal-title":"J. Natl. Med. Assoc."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0835","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/apt.15370","article-title":"Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease","volume":"50","author":"Korzenik","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0840","first-page":"93","article-title":"Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages\/neutrophils: protective and deleterious effects","volume":"22","author":"Grivennikov","year":"2005","journal-title":"Immunity."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0845","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.autrev.2023.103332_bb0850","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine."},{"key":"10.1016\/j.autrev.2023.103332_bb0855","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the control of the life and death balance of macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.autrev.2023.103332_bb0860","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20072707","article-title":"Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells","volume":"205","author":"Notley","year":"2008","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0865","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4049\/jimmunol.1500286","article-title":"Transmembrane TNF-TNFR2 impairs Th17 differentiation by promoting Il2 expression","volume":"195","author":"Miller","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0870","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41419-018-1266-6","article-title":"Differential roles of TNF\u03b1-TNFR1 and TNF\u03b1-TNFR2 in the differentiation and function of CD4(+)Foxp3(+) induced Treg cells in vitro and in vivo periphery in autoimmune diseases","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0875","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.0802948","article-title":"Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway","volume":"182","author":"Jacob","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.autrev.2023.103332_bb0880","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2018.00784","article-title":"Role of TNF-TNF receptor 2 signal in regulatory T cells and its therapeutic implications","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0885","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0890","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.autrev.2023.103332_bb0895","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. The yin-Yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.autrev.2023.103332_bb0900","doi-asserted-by":"crossref","DOI":"10.1186\/ar3431","article-title":"Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"13","author":"Chen","year":"2011","journal-title":"Arthrit. Res. Ther."},{"issue":"10","key":"10.1016\/j.autrev.2023.103332_bb0905","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0910","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"33","author":"Xueyi","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0915","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/art.27203","article-title":"Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells","volume":"62","author":"Ma","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2023.103332_bb0920","article-title":"Mechanisms of tumor necrosis factor-alpha inhibitor-induced systemic lupus erythematosus","volume":"9","author":"Yen","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103332_bb0925","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101478","article-title":"The pathogenic aspects","volume":"33","author":"Bugatti","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103332_bb0935","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway","volume":"121","author":"L\u00fcgering","year":"2001","journal-title":"Gastroenterology."},{"issue":"7","key":"10.1016\/j.autrev.2023.103332_bb0940","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology."},{"issue":"3","key":"10.1016\/j.autrev.2023.103332_bb0945","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"issue":"5 Suppl1","key":"10.1016\/j.autrev.2023.103332_bb0950","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.autrev.2023.103332_bb0955","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/rheumatology\/ken102","article-title":"Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis","volume":"47","author":"Watson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103332_bb0960","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00393-012-1054-0","article-title":"Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab","volume":"72","author":"Braun","year":"2013","journal-title":"Z. Rheumatol."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2023.103332_bb0965","first-page":"41","article-title":"Management of Rheumatoid Arthritis Patients with interstitial lung disease: safety of biological Antirheumatic drugs and assessment of pulmonary fibrosis","volume":"9","author":"Mori","year":"2015","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"issue":"8","key":"10.1016\/j.autrev.2023.103332_bb0970","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1053\/j.gastro.2020.01.017","article-title":"Anti-TNF Rechallenge after infliximab induced lupus in Crohn\u2019s disease","volume":"158","author":"Loebenstein","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.autrev.2023.103332_bb0975","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/831603","article-title":"Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs","volume":"2014","author":"Favalli","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.autrev.2023.103332_bb0980","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2013.06.008","article-title":"Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?","volume":"13","author":"Caporali","year":"2014","journal-title":"Autoimmun. Rev."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:56Z","timestamp":1761600536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":196,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1568997223000666"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103332","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103332"}}